Background-Dietary vitamin K is thought to be an important factor that interferes with anticoagulation stability, but the clinical applicability of this interaction has not been evaluated adequately in prospective studies. Methods and Results-In a randomized controlled trial that enrolled outpatients with a recent international normalized ratio (INR) outside the therapeutic target, we compared 2 strategies to optimize long-term oral anticoagulation: (1) a conventional approach based on changes in anticoagulant prescription and (2) a dietary vitamin K-guided strategy based on simple modifications of the amount of vitamin K-rich foods ingested per week. The primary efficacy end point was the percentage of patients who achieved a prespecified INR target at 90 days after randomization. Study population (nϭ132) predominantly included men with mechanical heart prostheses (58%) or atrial fibrillation (35%). Over time, patients allocated to the vitamin K-guided strategy reached the prespecified INR more frequently so that after 90 days of follow-up, 74% were on target compared with 58% of patients managed conventionally (Pϭ0.04). Patients allocated to the dietary vitamin K-guided strategy had the same magnitude and direction of INR variation as those observed with the conventional approach in the short term (15 days) for both underanticaogulated and overanticoagulated patients.
O ral anticoagulation has been used extensively for Ͼ50 years for prevention of thromboembolism in several cardiovascular conditions. 1 It is well recognized, however, that the effectiveness of oral anticoagulants in clinical practice is limited. A substantial percentage of patients cannot be maintained within the recommended therapeutic range, 2 despite major efforts from healthcare providers to meticulously adjust drug dosages and educate patients. Furthermore, the risk of major bleeding is a common concern and occurs in Ϸ2% to 3% annually, particularly in the elderly population. 3, 4 Therefore, identifying amenable factors that predict overanticoagulation or underanticoagulation has been the focus of intense basic and clinical research.
Clinical Perspective on p 1122
Genetic polymorphisms (CYP2C9 and VKORC1) have emerged as a potential explanation for the interindividual variability in dosing to reach the same therapeutic effects. 5 These factors, however, do not completely explain the considerable intraindividual instability of long-term oral anticoagulation. Reasons for this erratic behavior are unclear, but environmental factors are definitely involved, such as use of new medications and accidental increase of anticoagulant dose. 6, 7 In this scenario, the theoretical bases for drug-nutrient interactions with coumarin derivatives are convincingly established, particularly with respect to vitamin K. 8 Vitamin K is an essential cofactor for the synthesis of carboxyglutamic acid, a critical step in the activation of 4 coagulation factors (II, VII, IX, and X) and proteins C and S. 9, 10 Although the impact of dietary vitamin K intake on long-term oral anticoagulation has been recognized for Ͼ30 years, 11 recent prospective evidence suggests that this interaction is clinically relevant and might be a major independent factor that interferes with anticoagulation stability. [12] [13] [14] The potential clinical applicability of this interaction, however, has not been explored adequately in prospective studies. In the present protocol, we hypothesized that a simple vitamin K-guided management strategy to adjust oral anticoagulation would be feasible and safe and could result in improved long-term oral anticoagulation compared with the traditional adjustment strategy based on changes in dosage of anticoagulants.
Methods

Design Overview
We conducted an investigator-initiated, single-center, open, randomized clinical trial comparing 2 strategies for the adjustment of long-term oral anticoagulation: (1) conventional management based on changes in anticoagulant prescription and (2) a dietary vitamin K-guided approach. The study was conducted according to the Declaration of Helsinki, and the Ethics and Research Committee of Hospital de Clínicas de Porto Alegre approved the research protocol. All patients gave their written informed consent before study enrollment. The protocol was registered at ClinicalTrials.gov (http:// clinicaltrials.gov) as NCT00355290.
Setting and Participants
Patients were selected from the Oral Anticoagulation Clinic from Hospital de Clínicas de Porto Alegre, a tertiary care university hospital in the South Region in Brazil. The Oral Anticoagulation Clinic in our institution is nurse-practitioner operated and physician supervised, according to internationally accepted protocols and algorithms. 15 Patients eligible for inclusion in the study had to be on long-term oral anticoagulation therapy for Ͼ3 months, with the last international normalized ratio (INR) outside the therapeutic target, according to a prespecified range defined by the attending physician, without a definite cause for instability. For atrial fibrillation, INR target was 2.5 (from 2.0 to 3.0), and eligibility was considered if the observed INR was 1.5 to 1.99 or 3.01 to 4.0. For valvular prosthesis, the INR target for most patients was 3.0 (from 2.5 to 3.5), and eligibility was considered if the observed INR was 1.5 to 2.49 or 3.51 to 4.0 ( Table 1) . Definite cause for instability was defined as INR outside the prespecified therapeutic range caused by excessive accidental use of anticoagulants, fortuitous suspension of anticoagulants, other known pharmacological interactions, or clinical conditions (advanced malignancy, recent diarrheal illness, or recent hospitalization) that interfere with anticoagulation stability. Exclusion criteria were (1) extremes of INR values (Ͻ 1.5 or Ͼ4.0) (Table 1) or (2) evidence of clinical bleeding or thrombosis. No patient was enrolled more than once in the protocol.
Randomization and Interventions
Randomization was performed with a random number generator process and stratified by INR strata (overanticoagulation or underanticoagulation).
Dietary Vitamin K-Guided Management
Patients allocated to the dietary vitamin K-guided strategy were interviewed by a trained nurse, who assessed vitamin K intake using a previously validated 6,13 instrument to evaluate usual consumption of 16 vitamin K-rich foods (ranging from 20 to Ϸ700 g per 100 g): spinach, green tea, turnips, broccoli, brussel sprouts, cabbage, lettuce, vegetable oil (soy and canola), liver, watercress, green peas, asparagus, cauliflower, collard greens, cucumber, and rocket (rucula) ( Table I in the online-only Data Supplement). This instrument was proposed by Hylek et al 6 and asked patients to contrast their usual consumption of specific foods high in vitamin K content with the intake of these same items during the week preceding their prothrombin time test. We slightly modified this questionnaire and applied it in a prospective observational analysis in patients from our anticoagulation clinic, demonstrating that a dietary vitamin K score correlated inversely with the level of anticoagulation. 13 The instrument was designed to allow a broad clinical applicability and has a weak to moderate correlation with quantitative assessment in milligrams of intake based on comprehensive food diaries (data not shown). On the basis of this initial assessment, patients were oriented to reduce by half (50% decrease) the ingestion of vitamin K-rich food items if they were underanticoagulated or to double (100% increase) the ingestion of vitamin K-rich food if they were overanticoagulated ( Table 2) . Dietary orientations were based exclusively on changes in the number of times each food item was ingested per week. Specifically, if a patient's vitamin K consumption was based on the ingestion of 3 food items (eg, lettuce, broccoli, and liver) 4 times per week each and the measured INR was below target, dietary orientation would be to decrease the ingestion of the same food items to 2 times per week. No explicit instruction on food quantity was specified. During the trial, patients allocated to the dietary vitamin K strategy were exceptionally compliant with dietary orientations. At baseline, all patients had a minimal consumption that allowed modulation of intake. Dosage of anticoagulant drugs was not altered in the dietary vitamin K-guided management group. Patients were reevaluated after 15, 30, 60, and 90 days, with reassessment of dietary vitamin K intake with the use of the same instrument and new measurements of prothrombin time. Patients who achieved the therapeutic target during follow-up were oriented to maintain the same intake of vitamin K-rich foods. Patients who did not reach the target INR were reoriented to change vitamin K intake on the basis of the same algorithm. Crossover to the conventional management strategy was indicated by protocol if 3 consecutive INRs were outside the therapeutic target, if a single INR was Ͼ6.0, or if clinical signs of bleeding or thrombosis were identified.
Conventional Management Strategy
Patients allocated to the conventional management were oriented to decrease or increase oral anticoagulants according to internationally accepted guidelines and algorithms 15 (Table 2) . At the initial visit, baseline vitamin K intake was also evaluated in these patients. Patients were reevaluated after 15, 30, 60, and 90 days with reassessment of dietary vitamin K intake with the use of the same instrument and new measurements of prothrombin time. No change in vitamin K intake was indicated during follow-up in the conventional management group. Adherence to anticoagulant drugs and dosages was actively pursued during each follow-up visit.
Outcomes and Follow-Up
The primary efficacy end point was the percentage of included patients who achieved the prespecified INR target range 90 days after randomization on a single INR measurement. Secondary end points were the percentage of patients who reached the prespecified target 15, 30, and 60 days after randomization; overall percentage of patients on target during follow-up irrespective of time periods, evidence of minor and major bleeding, or thrombosis during followup; and effect of each intervention (conventional or vitamin K guided) on anticoagulation parameters on day 15.
Statistical Analysis
Continuous variables with normal distribution were expressed as meanϮSD, and categorical data were expressed as numbers and percentages. Comparisons between groups were performed with the 2 test and Fisher exact test for categorical variables and Student t test or Wilcoxon test for continuous variables. Analysis for repeated measures was performed to evaluate the time, group, and time-group interaction for the percentage of patients who reached the target in different time points with the use of the CATMOD procedure (SAS 9.0 for Windows). For missing data (nϭ3) on day 90 of follow-up (primary end point), the preceding available INR value was interpolated for statistical purposes. All analyses were based on the intention-to-treat principle. For comparisons of baseline and 15-day INRs, we performed a paired t test; the differences between interventions at 15 days were evaluated by comparing the differences in INRs according to baseline stratum. General linear models were used to compare the number of vitamin K-rich food items between groups in different time points; post hoc analysis was performed by the Student-Newman-Keuls multiple range test. A sample size of 114 patients was calculated to test the primary hypothesis. This number provided a statistical power of 80% at 5% significance level to detect a 25% absolute increment in the percentage of patients that would achieve the therapeutic target (from 60% in the conventional group to 85% in the vitamin K management strategy). A 2-sided P value Ͻ0.05 was considered statistically significant. Data were analyzed with the statistical package SAS 9.0 for Windows (SAS Institute Inc, Cary, NC).
Results
Studied Population
From March 2006 through September 2007, potentially eligible patients were screened from the outpatient oral anticoagulation clinic at Hospital de Clínicas de Porto Alegre. Of 801 patients who were screened, 132 subjects fulfilled the entry criteria and consented to participate in the protocol (Figure 1 ), evenly distributed in both groups of intervention. The major criterion for noneligibility was related to patients who already had their INR on target. Although the entry criterion requested only 1 INR outside the target, 49% of patients in the trial had 2 consecutive INRs outside the target before enrollment, evenly distributed between groups. After randomization, 1 patient died in the vitamin K-guided management group, and 2 did not complete the 90-day follow-up visit in the conventionally treated group. The only death during follow-up was not related to clinical bleeding or thrombosis (septic shock with multiple organ failure). The study population included predominantly male subjects with mechanical heart prostheses (58%) or atrial fibrillation (35%). Most patients were receiving warfarin as the anticoagulant drug, but 20 (15%) were using phenprocoumon. All baseline clinical characteristics were similar between treatment strategies, including socioeconomic parameters, duration of long-term oral anticoagulation, and clinical comorbidities (Table 3 ). Baseline intake of vitamin K assessed by the semiquantitative instrument was comparable between both groups for high, moderate to high, and moderate intake of vitamin K-rich foods ( Table 4 ).
Main Outcomes
As defined by protocol, all patients were outside the target INR at baseline. Overall, 94 patients (71%) were underanticoagulated, and 38 (29%) were overanticoagulated, according to a predefined target, and evenly distributed in the groups of intervention. At short-term follow-up, no clinically meaningful differences were observed between both treatment strate- 
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Vitamin K and Oral Anticoagulation gies. Over time, patients allocated to the vitamin K-guided strategy reached the prespecified INR progressively more frequently, so that after 90 days of follow-up, 74% were on target compared with 58% of the patients managed conventionally (Pϭ0.04; Figure 2 ). In this analysis, we observed a significant effect of time and group allocation, but the time-group interaction (slope of increment in patients achieving the INR target) was not significantly different (CATMOD procedure Minor bleeding or use of parenteral vitamin K occurred in 7 patients (11%) of the conventionally treated group (2 patients with hemoptysis, 1 with hematuria, 1 with gingival bleeding, 1 with skin ecchymosis, and 2 who received intravenous vitamin K), whereas no patient had minor bleeding, and only 1 patient (1.5%) received parenteral vitamin K (asymptomatic INR Ͼ7) in the vitamin K-guided strategy. This difference was marginally statistically significant (Pϭ0.06, Fisher exact test).
Short-Term Effect of Treatment Strategies on Anticoagulation Parameters (Proof of Concept)
Dietary Vitamin K-Guided Strategy
We evaluated the short-term effect of the vitamin K-guided strategy on coagulation parameters by comparing basal INRs versus INRs at 15 days, after the first phase of dietary orientations, stratified by coagulation status at baseline. Figure 3A illustrates the effect of decreasing dietary vitamin K intake in the underanticoagulated patients at baseline (nϭ47). We observed a 23% statistically significant increase in INRs after dietary orientations (basal to 15-day INR, from 2.0Ϯ0.3 to 2.5Ϯ0.7; PϽ0.001). In the underanticoagulated patients, 42 of 47 patients (89%) increased their INR after the dietary intervention. Likewise, Figure 3B demonstrates a 19% statistically significant decrease in INRs in the overanticoagulated patients at baseline (nϭ19) after they were oriented to increase their dietary vitamin K intake (basal to 15-day INR, from 3.6Ϯ0.3 to 2.9Ϯ0.9; PϽ0.001). In the overanticoagulated patients, 16 of 19 patients (84%) decreased their INR after the dietary intervention. Figure 3C illustrates the effect of increasing anticoagulant dose in the underanticoagulated patients at baseline (nϭ47). We observed a 30% statistically significant increase in INRs (basal to 15-day INR, from 1.9Ϯ0.3 to 2.7Ϯ0.7; PϽ0.001).
Conventional Strategy
In the underanticoagulated patients, 41 of 47 patients (87%) increased their INR after adjustments of the anticoagulant dosage. Figure 3D 
Comparisons at Short Term
Adherence to the Conventional and Vitamin K-Guided Strategies and Crossovers
Adherence to anticoagulant drugs and to dietary vitamin K orientations was evaluated in both groups. In particular, we were concerned that the conventional strategy could be influenced by previous orientations about the importance of dietary vitamin K or by unplanned contact during the trial with patients allocated to this strategy. Figure 4 depicts the ingestion of dietary vitamin K-rich foods in both groups in all time periods, according to basal INR strata (underanticoagulated or overanticoagulated patients). In the underanticoagulated group at baseline, patients who were allocated to the dietary intervention reduced substantially the number of vitamin K-rich foods ( Figure 4A, left) , whereas in the overanticoagulated group at baseline, patients increased the number of vitamin K-rich foods but to a lesser magnitude of increment variation (Figure 4B, left) . No significant changes in the number of vitamin K-rich food items were observed in the conventionally treated patients ( Figure 4A and 4B, right) .
Overall, adhesion to anticoagulants was very good during the trial; only 17 patients declared that they had forgotten to follow the prescribed dose for a short period of time during follow-up (12 subjects in the conventionally treated group: mean of 0.8Ϯ2.4 days [median, 0 days], ranging from 0 to 14 days; 5 subjects in the vitamin K-guided group: mean of 0.5Ϯ2 days [median, 0 days], ranging from 0 to 13 days). Crossover to the conventional group occurred in 11 patients (16.6%) because target INR was not achieved on 3 consecutive INRs. Importantly, the majority of these patients (7 of 11) did not achieve final INR target, and 3 of the crossovers had a final INR Ͼ4.0.
Discussion
A growing body of clinical evidence has recently strengthened the concept that the interaction between dietary vitamin K and oral anticoagulants is clinically relevant and may represent a major factor that interferes with anticoagulation stability. However, the proper approach to deal with this interaction in clinical practice has not been elucidated entirely. In the present randomized protocol, we have demonstrated that a strategy based on changes in vitamin K intake is feasible and safe. Moreover, patients allocated to the dietary vitamin K-guided strategy had the same magnitude and direction of INR variation as those observed with the conventional approach in the short term but reached the target INR significantly more frequently after 90 days of intervention.
There is a solid mechanistic basis for the interaction between vitamin K and oral anticoagulant drugs. Vitamin K in its hydroquinone form is an essential cofactor for carboxyglutamic acid synthesis, a critical step in the activation of several coagulation factors and proteins C and S. 10 Through this process, reduced vitamin K 1 is oxidized to its epoxide form, and enzymatic regeneration by a reductase system is needed to produce new hydroquinone vitamin K. This cycle is inhibited by warfarin, phenprocoumon, and acenocoumarol through the interaction with fundamental vitamin K-regenerating enzymes. Increased availability of vitamin K is a key factor that can antagonize the effect of oral anticoagulants. The major sources of dietary vitamin K are well known and come from dark-green or deep-yellow leafy vegetables and animal viscera, particularly beef liver. 16 -18 A recent report also indicates that long-chain vitamin K 2 (menaquinone-7) from over-the-counter supplements can interfere with oral anticoagulant treatment. 19 Udall 11 in 1965 was the first investigator to evaluate the effects of dietary vitamin K on coagulation parameters in the clinical arena, studying healthy subjects who were fed a diet and overanticoagulated patients at baseline (B). Time-group interaction P values (GLM procedure) were 0.61, Ͻ0.001, and 0.008 for high, moderate to high, and moderate intake of vitamin K-rich foods, respectively, for underanticoagulated patients at baseline (A) and 0.36, 0.04, and 0.39 for high, moderate to high, and moderate intake of vitamin K-rich foods, respectively, for overanticoagulated patients at baseline (B).
low in vitamin K. Several case reports subsequently described the potential association between vitamin K intake and coagulation instability. 20 -23 In the last decade, observational protocols and small prospective intervention reports evaluated this interaction. 24 -27 Most of these studies were consistent with the concept that vitamin K, particularly from dietary sources, may substantially alter coagulation parameters and may result in the risk of overanticoagulation or underanticoagulation. We have previously demonstrated in a prospective randomized crossover protocol that even brief periods of increased or decreased vitamin K intake significantly change prothrombin times. 13 The precise amount of dietary or supplementary vitamin K to be offered for anticoagulated patients, however, is not well established. Kahn and coworkers 28 estimated by dietary records that for each increase of 100 g of vitamin K intake averaged over 4 days, the INR would be reduced by 0.2. The same group of investigators subsequently demonstrated that unstable control of oral anticoagulation was associated with lower mean daily intake of vitamin K. These authors suggested that daily supplementation with oral vitamin K could be an adequate strategy to lead to more stable anticoagulation. 29 In a double-blind protocol, patients who received supplementation had a small but significant increase in the time within the target INR range. 30 These results, however, were not fully confirmed by a recent double-blind, randomized trial involving 200 anticoagulated patients who received 100 g of oral vitamin K once daily or placebo for 24 weeks. 31 Taken together, these results suggest that fixed vitamin K supplementation could be an adequate approach in a selected subgroup of anticoagulated patients, but the improvement in INR stability may be suboptimal. In addition, deliberately increasing vitamin K intake in underanticoagulated patients (71% of our sample) might even be detrimental because it would antagonize even further the effect of oral anticoagulants.
In the present protocol, we propose a novel approach to improve anticoagulation stability. On the basis of a semiquantitative questionnaire that assesses usual consumption of vitamin K, anticoagulated patients outside their INR target were oriented to decrease or increase their own consumption of vitamin K-rich foods, irrespective of baseline consumption. The intrinsic validity of this pragmatic and clinically driven approach was confirmed by the exceptional effect of this strategy to correct INRs in both underanticoagulated and overanticoagulated patients. After 90 days of sequential dietary orientations, patients allocated to the dietary vitamin K-guided group were 16% more likely to be within the INR target than patients managed conventionally. The uniqueness of the proposed strategy relies on the opportunity to continuously educate patients about the importance of dietary vitamin K, trying at the same time to individually modulate its intake on the basis of their own dietary patterns. In this scenario, it is important to recognize that dietary intake of vitamin K is variable in different populations and age strata 6 and may depend on seasonal availability of different food items.
Some methodological aspects of our protocol deserve consideration. We deliberately opted to use a semiquantitative evaluation of vitamin K that does not precisely estimate daily consumption. A more detailed assessment and modula-tion of vitamin K ingestion could potentially increase the magnitude of benefit of the proposed intervention but would limit the clinical applicability of such strategy. In addition, the relatively short-term follow-up of the present protocol does not ensure that the clinical benefit of reaching INR targets would be maintained over 3 months. Adherence to dietary counseling and the cost-effectiveness of the proposed strategy are important concerns that must be addressed directly in future studies. We acknowledge that an open design may be intrinsically influenced by both patient and investigator bias. One could argue that part of the observed benefit could be attributed to improved adherence to treatment and a greater level of attention to patients in the dietary intervention strategy. We believe that this is highly unlikely because the number and duration of clinical visits were identical between groups. Finally, an open design also involves the risk of human influence on findings. In particular, the conventional group might have been influenced by previous knowledge about vitamin K intake or by the fact that they were directly asked about vitamin K consumption during the trial. This potential bias, however, would most likely decrease the magnitude of the differences we found between groups (conservative bias). We believe that an investigatordriven bias was unlikely because both strategies were efficacious in correcting INRs at short-term follow-up and because anticoagulant dose changes in the conventionally treated patients were based on internationally accepted algorithms, with limited flexibility. Achieving oral anticoagulation stability over time is a challenging task. Dietary vitamin K is an aspect of this complex clinical dilemma that has been greatly overlooked by physicians, nurses, and pharmacists. We now have solid prospective clinical evidence that modulation of dietary vitamin K is a feasible approach to reach anticoagulation stability. Our data indicate that changes in dietary vitamin K intake are an efficacious strategy to increase the probability of achieving INRs within the therapeutic range.
However, we should not send the wrong message of indiscriminately decreasing dietary vegetable content because the background message of our findings is that anticoagulated patients should maintain a steady intake of vitamin K once INR stability has been achieved.
